# Tirzepatide FAQ — common questions about the dual GIP/GLP-1 receptor agonist > Answers to the most common questions about tirzepatide: how it works, what the SURMOUNT-1 weight-loss numbers were, dose titration, side effects, half-life, cardiovascular outcomes, sleep apnea, MASH, and what happens after stopping. Questions, with sources. Short answers grounded in the same trial record covered on the rest of the site. Each answer cites a primary source on the references page. ## What is tirzepatide and how does it work? Tirzepatide is a once-weekly subcutaneous injection that activates two gut-hormone receptors with one molecule: the GIP receptor (glucose-dependent insulinotropic polypeptide) and the GLP-1 receptor (glucagon-like peptide-1) [14]. Engaging both pathways enhances meal-stimulated insulin secretion, suppresses glucagon, slows how quickly the stomach empties, and reduces appetite through hypothalamic signaling. The peptide is engineered with a fatty di-acid chain that binds reversibly to blood albumin, giving it a five-day half-life and enabling weekly dosing [15]. It is FDA-approved for type 2 diabetes (2022), chronic weight management (2023), and moderate-to-severe obstructive sleep apnea in adults with obesity (2024). ## What is the difference between tirzepatide and a single GLP-1 agonist? A selective GLP-1 receptor agonist activates one incretin pathway. Tirzepatide activates two — GIP and GLP-1 — with one molecule. In SURPASS-2, the head-to-head trial against injectable semaglutide 1 mg in adults with type 2 diabetes on metformin, all three tirzepatide doses produced superior HbA1c and body weight reductions over 40 weeks. The composite endpoint of HbA1c at or below 6.5% with at least 10% weight loss was reached by 60% of the tirzepatide 15 mg arm versus 22% on semaglutide [3]. Receptor-pharmacology work suggests tirzepatide is a biased GLP-1 receptor agonist that favors cAMP signaling and reduces receptor internalization compared with native GLP-1, alongside balanced GIP receptor activation [14]. ## What did SURMOUNT-1 actually show for weight loss? SURMOUNT-1 was a 72-week placebo-controlled trial in 2,539 adults with obesity (BMI at least 30) or overweight (BMI at least 27 with a weight-related comorbidity), without type 2 diabetes. Mean body weight reductions were 16.0% on 5 mg, 21.4% on 10 mg, and 22.5% on 15 mg, versus 2.4% on placebo. At the 15 mg dose, 91% of participants lost at least 5% of their starting body weight [1]. These are average effects across a large randomized cohort; individual responses varied. SURMOUNT-2, which enrolled adults with both obesity and type 2 diabetes, produced somewhat smaller mean reductions (15.7% on 15 mg) — consistent with the broader pattern that weight loss tends to be blunted when type 2 diabetes is present [7]. ## How is tirzepatide dosed? What is the titration schedule? Every patient starts at 2.5 mg once weekly for four weeks. That starting dose is explicitly non-therapeutic — it is there only to help the digestive system acclimate. After week 4, the dose increases to 5 mg weekly. If additional glycemic or weight control is needed, it can be increased in 2.5 mg increments at intervals of at least four weeks, up to a maximum of 15 mg weekly. The labeled maintenance doses are 5 mg, 10 mg, and 15 mg; the 7.5 mg and 12.5 mg strengths exist as titration steps [16][17]. Slow titration is the main mitigation for the gastrointestinal side effects that cluster during dose escalation. ## What are the most common side effects of tirzepatide? A pooled safety analysis of SURMOUNT-1 through -4 found that gastrointestinal events were the most common adverse events, typically mild to moderate, transient, and concentrated during dose escalation. Reported incidence ranges were nausea 24-33%, diarrhea 19-23%, vomiting 8-16%, and constipation 12-17% across labeled doses. Discontinuation due to gastrointestinal events ranged from 3-7% [16]. Post-marketing pharmacovigilance has also flagged disproportionality signals for acute pancreatitis, cholelithiasis (gallstone disease), and ileus, consistent with the prescribing-information warnings [17]. The boxed warning concerns thyroid C-cell tumors, based on rodent studies; human relevance has not been established. ## What is the half-life of tirzepatide? The terminal elimination half-life is approximately five days (about 120 hours), based on a population pharmacokinetic model built from 5,798 participants across phase 1, 2, and 3 trials [15]. Median time to peak concentration is 24 hours after a subcutaneous dose (range 8 to 72 hours). Steady state is reached after about four weekly doses. Mean absolute subcutaneous bioavailability is approximately 80%. The five-day half-life is what makes a once-weekly injection schedule biologically reasonable — concentrations do not return to baseline between doses. ## Does tirzepatide protect against cardiovascular events? SURPASS-CVOT, published in 2025, was the dedicated cardiovascular outcomes trial. It enrolled adults with type 2 diabetes and elevated cardiovascular risk and compared maximum-tolerated tirzepatide with dulaglutide 1.5 mg weekly over a median four-year follow-up. The primary composite of cardiovascular death, myocardial infarction, or stroke occurred in 12.2% of the tirzepatide group versus 13.1% of the dulaglutide group, meeting the non-inferiority threshold but not superiority (P=0.09). All-cause mortality was 16% lower in relative terms with tirzepatide [13]. SURPASS-4 had separately reported a MACE-4 hazard ratio of 0.74 in adults with type 2 diabetes and elevated cardiovascular risk, with no signal of increased cardiovascular risk [5]. Systolic blood pressure also dropped 4-6 mmHg across SURPASS-1 through -5 [18]. ## What conditions is tirzepatide FDA-approved for? Three approvals as of late 2024: - Type 2 diabetes (May 13, 2022) — as an adjunct to diet and exercise to improve glycemic control in adults. - Chronic weight management (November 8, 2023) — in adults with obesity (BMI at least 30) or overweight (BMI at least 27) with at least one weight-related comorbidity. - Obstructive sleep apnea (December 20, 2024) — moderate-to-severe OSA in adults with obesity, based on the SURMOUNT-OSA trial [10]. Research in heart failure with preserved ejection fraction (SUMMIT) [11] and metabolic-dysfunction-associated steatohepatitis (SYNERGY-NASH) [12] is positive but does not yet correspond to an approved indication. ## What happens if tirzepatide is stopped? SURMOUNT-4 was designed specifically to answer this question. After 36 weeks of open-label tirzepatide — during which participants lost about 21% of body weight on average — they were randomized to continue tirzepatide or switch to placebo for another 52 weeks. Continued treatment maintained 25.3% total weight loss at 88 weeks. The placebo group regained 14.0 percentage points of body weight over the same period [9]. The result frames tirzepatide-supported weight loss as ongoing pharmacotherapy for a chronic condition rather than a finite course of treatment. Lean-mass loss alongside fat-mass loss has also been described with rapid weight reduction, and resistance training plus adequate dietary protein have been studied as mitigation strategies. ## Is tirzepatide effective for sleep apnea, MASH, or heart failure? Recent trials suggest yes for all three, though the regulatory status differs. SURMOUNT-OSA reported up to a 63% reduction in apnea-hypopnea index at 52 weeks in adults with moderate-to-severe obstructive sleep apnea and obesity [10], which supported the December 2024 FDA approval. SUMMIT showed a lower composite of cardiovascular death or worsening heart failure (hazard ratio 0.62) and improved exercise tolerance in heart failure with preserved ejection fraction and obesity [11]. SYNERGY-NASH demonstrated 73.3% MASH resolution on 15 mg versus 13.2% on placebo at 52 weeks, with a trend toward fibrosis improvement at higher doses [12]. HFpEF and MASH approvals do not yet exist; these data are evidence for benefit, not labeled indications. ## What about compounded tirzepatide? During the FDA-declared shortage that began in late 2022, U.S. compounding pharmacies were permitted to prepare tirzepatide under sections 503A and 503B of the Food, Drug, and Cosmetic Act. The shortage was resolved on October 2, 2024 and reaffirmed in a December 19, 2024 declaratory order. The 503A compounding period sunset on February 18, 2025 and the 503B period sunset on March 19, 2025. After those dates, compounded tirzepatide is no longer permitted under U.S. compounding law. Compounded preparations are not evaluated for identity, strength, quality, or purity by the FDA. ## Is tirzepatide a weight-loss drug or a diabetes drug? Both — but the approvals came in sequence and the drug is one molecule used across multiple indications. The first approval (2022) was for type 2 diabetes. The second (2023) was for chronic weight management in adults with obesity or overweight with a comorbidity. The third (2024) was for obstructive sleep apnea in adults with obesity. The same molecule, the same titration ladder, the same maximum dose. Whether tirzepatide is described as a diabetes drug or a weight-loss drug usually reflects which indication brought the patient to it — not a different formulation. ## Does this site sell tirzepatide? No. Shop Tirzepatide is an independent editorial project that summarizes published research on the compound. It is not a pharmacy, telehealth service, compounder, or vendor of any kind. It does not sell or distribute tirzepatide or any other product, and it is not affiliated with any manufacturer. The word "shop" in the domain refers to how the content is organized — a catalog of trials and approved indications — not to a transaction. Decisions about prescription tirzepatide belong with a licensed clinician. ## References [1] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022. doi:10.1056/NEJMoa2206038 [3] Frias JP, et al. Tirzepatide vs Semaglutide in T2DM. NEJM. 2021. doi:10.1056/NEJMoa2107519 [5] Del Prato S, et al. SURPASS-4: tirzepatide vs insulin glargine in elevated CV risk T2DM. Lancet. 2021. doi:10.1016/S0140-6736(21)02188-7 [7] Garvey WT, et al. SURMOUNT-2. Lancet. 2023. doi:10.1016/S0140-6736(23)01200-X [9] Aronne LJ, et al. SURMOUNT-4. JAMA. 2024. doi:10.1001/jama.2023.24945 [10] Malhotra A, et al. SURMOUNT-OSA. NEJM. 2024. doi:10.1056/NEJMoa2404881 [11] Packer M, et al. SUMMIT (HFpEF). NEJM. 2024. doi:10.1056/NEJMoa2410027 [12] Loomba R, et al. SYNERGY-NASH. NEJM. 2024. doi:10.1056/NEJMoa2401943 [13] Bhatt DL, et al. SURPASS-CVOT. NEJM. 2025. doi:10.1056/NEJMoa2505928 [14] Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP/GLP-1 receptor agonist. JCI Insight. 2020. doi:10.1172/jci.insight.140532 [15] Furihata K, et al. Population pharmacokinetics of tirzepatide. CPT: PSP. 2024. doi:10.1002/psp4.13110 [16] Rubino DM, et al. GI tolerability across SURMOUNT-1 to -4. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16176 [17] Caruso I, et al. Real-world safety profile of tirzepatide (FAERS). J Endocrinol Invest. 2024. doi:10.1007/s40618-024-02441-z [18] de Boer IH, et al. SBP reduction with tirzepatide (SURPASS pool). Cardiovascular Diabetology. 2023. doi:10.1186/s12933-023-01775-x --- Not medical advice. This site does not sell any product and is not affiliated with any vendor or manufacturer.